Literature DB >> 9603169

Gender-related assessment of cyclosporine/prednisolone/sirolimus interactions in three human lymphocyte proliferation assays.

G M Ferron1, N A Pyszczynski, W J Jusko.   

Abstract

BACKGROUND: Cyclosporine (CsA), prednisolone (Pred), and sirolimus (Sir) are immunosuppressive compounds inhibiting lymphocyte proliferation at the cytokine gene transcription (CsA and Pred) or signal transduction (Sir) levels.
METHODS: Double- and triple-drug interactions were simultaneously studied using lectin-induced proliferation of isolated cell lymphocytes (ICLP) and whole blood lymphocytes from men and women as well as two-way mixed lymphocyte reaction assays. Drug interactions were described with isobolograms and quantitated with the universal response surface approach by estimating the interaction parameter alpha.
RESULTS: All compounds inhibited more than 89% of control proliferative responses. In each assay, CsA was less potent than Pred (3- to 14-fold) and Sir (5- to 11-fold). Sir was of similar or higher potency than Pred and 1.5-fold more potent in men than women. Pred was 1.4 times more potent in women but this was found only in the ICLP assay. All combinations were synergistic (alpha>0), with greater synergism found for combinations involving Sir, especially in the ICLP (alpha>13) and two-way mixed lymphocyte reaction (alpha>40) assays. Moreover, the Sir/Pred interaction in the ICLP assay was two to five times more synergistic in women, because their mean alpha was 56 compared with 13 in men. Double-combination alpha values were able to reasonably describe CsA/Pred/Sir triple-interaction effects.
CONCLUSIONS: These studies indicate that CsA, Pred, and Sir act and synergistically interact in vitro, with gender and assay as additional factors, and that whole blood lymphocyte proliferation cultures are useful in assessing the nature and intensity of drug interactions.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9603169      PMCID: PMC4207307          DOI: 10.1097/00007890-199805150-00011

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  32 in total

Review 1.  New glucocorticoids. Mechanisms of immunological activity at the cellular level and in the clinical setting.

Authors:  M Scudeletti; L Castagnetta; B Imbimbo; F Puppo; I Pierri; F Indiveri
Journal:  Ann N Y Acad Sci       Date:  1990       Impact factor: 5.691

Review 2.  Sirolimus: a new agent for clinical renal transplantation.

Authors:  B D Kahan
Journal:  Transplant Proc       Date:  1997 Feb-Mar       Impact factor: 1.066

3.  Increased cardiac allograft rejection in female heart transplant recipients.

Authors:  B G Crandall; D G Renlund; J B O'Connell; N A Burton; K W Jones; W A Gay; D B Doty; S V Karwande; H R Lee; C Holland
Journal:  J Heart Transplant       Date:  1988 Nov-Dec

4.  The side effect profile of sirolimus: a phase I study in quiescent cyclosporine-prednisone-treated renal transplant patients.

Authors:  M G Murgia; S Jordan; B D Kahan
Journal:  Kidney Int       Date:  1996-01       Impact factor: 10.612

5.  Immunophilins, Heat Shock Proteins, and Glucocorticoid Receptor Actions in Vivo

Authors: 
Journal:  Methods       Date:  1996-04       Impact factor: 3.608

6.  Novel mechanism for inhibition of human T cells by glucocorticoids. Glucocorticoids inhibit signal transduction through IL-2 receptor.

Authors:  F Paliogianni; S S Ahuja; J P Balow; J E Balow; D T Boumpas
Journal:  J Immunol       Date:  1993-10-15       Impact factor: 5.422

7.  The effect of dexamethasone, cyclosporine, and rapamycin on T-lymphocyte proliferation in vitro: comparison of cells from patients with glucocorticoid-sensitive and glucocorticoid-resistant chronic asthma.

Authors:  A Haczku; A Alexander; P Brown; B Assoufi; B Li; A B Kay; C Corrigan
Journal:  J Allergy Clin Immunol       Date:  1994-02       Impact factor: 10.793

8.  Direct stimulation of cytokines (IL-1 beta, TNF-alpha, IL-6, IL-2, IFN-gamma and GM-CSF) in whole blood. I. Comparison with isolated PBMC stimulation.

Authors:  D De Groote; P F Zangerle; Y Gevaert; M F Fassotte; Y Beguin; F Noizat-Pirenne; J Pirenne; R Gathy; M Lopez; I Dehart
Journal:  Cytokine       Date:  1992-05       Impact factor: 3.861

9.  Stabilization in vitro of the untransformed glucocorticoid receptor complex of S49 lymphocytes by the immunophilin ligand FK506.

Authors:  Y M Ning; E R Sanchez
Journal:  J Steroid Biochem Mol Biol       Date:  1995-02       Impact factor: 4.292

10.  The effect of FK506 versus cyclosporine on glucose and lipid metabolism--a randomized trial.

Authors:  T M Steinmüller; K J Gräf; J Schleicher; K Leder; W O Bechstein; A R Mueller; K Dette; E Schulz; P Neuhaus
Journal:  Transplantation       Date:  1994-09-27       Impact factor: 4.939

View more
  4 in total

1.  Treatment of Severe Alopecia Areata: Combination Therapy Using Systemic Cyclosporine A with Low Dose Corticosteroids.

Authors:  Deborah Lee; Doo Jin Oh; Jung Wook Kim; Sung Wook Park; Min Kyung Oh; Ho Suk Sung; Seon Wook Hwang
Journal:  Ann Dermatol       Date:  2008-12-31       Impact factor: 1.444

2.  Parabolic growth patterns in 96-well plate cell growth experiments.

Authors:  H M Faessel; L M Levasseur; H K Slocum; W R Greco
Journal:  In Vitro Cell Dev Biol Anim       Date:  1999-05       Impact factor: 2.416

3.  Interactions of everolimus and sorafenib in whole blood lymphocyte proliferation.

Authors:  Dipti K Pawaskar; Robert M Straubinger; Gerald J Fetterly; Wen W Ma; William J Jusko
Journal:  Pharm Res       Date:  2012-11-14       Impact factor: 4.200

4.  Comparison of High-Dose Corticosteroid Pulse Therapy and Combination Therapy Using Oral Cyclosporine with Low-Dose Corticosteroid in Severe Alopecia Areata.

Authors:  In Kwon Yeo; Eun Jung Ko; Yeon A No; Ee Seok Lim; Kui Young Park; Kapsok Li; Beom Joon Kim; Seong Jun Seo; Myeung Nam Kim; Chang Kwun Hong
Journal:  Ann Dermatol       Date:  2015-12-07       Impact factor: 1.444

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.